Solara Active Pharma Sciences Ltd (SOLARA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Solara Active Pharma Sciences Ltd on NSE and BSE, with an AI summary of each filing.
Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended September 30, 2026
Transcript · 23 Oct 2026, 10:12 pm
Solara Active Pharma Sciences Limited has informed the Exchange regarding the dispatch of Final Reminder -cum-Forfeiture Notice for the payment of outstanding call money to the holders ....
Others (Uncategorized) · 18 Oct 2026, 12:20 am
Solara Active Pharma Sciences Issues Final Rights Call Money Reminder-Cum-Forfeiture Notice Solara Active Pharma Sciences has dispatched a final reminder-cum-forfeiture notice for outstanding call money on partly paid-up rights equity shares. Unpaid amounts include the First Call of ₹131.25 per share (₹3.50 face value, ₹127.75 premium) and the Second and Final Call of ₹112.50 per share (₹3.00 face value, ₹109.50 premium). The payment window opens on 22nd Oct'26 and closes on 5th Nov'26. Failure to pay within this period will result in the forfeiture of partly paid-up shares without further notice.
Monitoring Agency Report for the quarter ended September 30, 2026
Others (Uncategorized) · 17 Oct 2026, 12:59 am
Solara Active Pharma Reports Zero Deviation in Rights Issue Proceeds Utilization CRISIL Ratings issued the Monitoring Agency Report for Solara Active Pharma Sciences for the quarter ended 30th Sep'26, confirming zero deviation in rights issue proceeds utilization. Out of the revised net proceeds of Rs 446.95 crore, the company has deployed Rs 439.88 crore, including Rs 334.71 crore fully utilized toward debt repayment and Rs 105.17 crore toward general corporate purposes. Unutilized funds stand at Rs 7.07 crore, comprising Rs 3.33 crore yet to be received from calls and Rs 3.74 crore held across monitoring and escrow accounts.
Audio recordings of Q2 FY27 earnings call conducted on October 16, 2026, for the quarter ended September 30, 2026
Audio / Video · 17 Oct 2026, 12:53 am
Solara Active Pharma Uploads Q2 FY27 Earnings Call Audio Recording Solara Active Pharma Sciences has made available the audio recording of its Q2 FY27 earnings conference call conducted on 16th Oct'26 at 16:00 IST. The call discussed the company's unaudited financial results for the quarter ended 30th Sep'26. In compliance with SEBI Listing Regulations, the recording has been hosted on the company's official website under the Investor Relations section.
Solara Active Pharma Sciences Limited has informed the exchange about the Statement of Deviation/Variation in utilization of funds raised though Rights issue for the quarter ended September 30 2026
Others (Uncategorized) · 16 Oct 2026, 9:33 pm
Solara Reports Nil Deviation in Rights Issue Fund Utilization for Sep'26 Quarter Solara Active Pharma Sciences reported zero deviation in the utilization of its ₹446.62 crore Rights Issue proceeds for the quarter ended 30th Sep'26. Total funds deployed reached ₹442.88 crore, including ₹334.71 crore fully utilized for debt repayment/prepayment and ₹105.17 crore spent toward general corporate purposes against an allocated ₹112.24 crore. During the quarter, ₹1.25 crore was deployed (₹1.10 crore for debt reduction, ₹0.15 crore for corporate purposes). Remaining unutilized funds include ₹0.14 crore in escrow and ₹3.60 crore in the monitoring account.
Solara Active Pharma Sciences Limited has informed the Exchange regarding grant of 470000 options under Solara Employee Stock Option Plan 2024
Others (Uncategorized) · 16 Oct 2026, 7:28 pm
Solara Active Pharma Sciences Approves Grant of 4,70,000 ESOPs Solara Active Pharma Sciences Limited's Nomination and Remuneration Committee approved the grant of 4,70,000 stock options to eligible employees under the Solara Employee Stock Option Plan 2024 on 16th Oct'26. The options cover 4,70,000 equity shares at an exercise price of Rs. 375 per share. Grantees must exercise the options within 120 days from the vesting date, after which unexercised options will lapse.
Solara Active Pharma Sciences Limited has informed the Exchange regarding a Press Release dated October 16, 2026, titled "Solara''s Q2 FY 27 revenue grows 33% to INR 4,178 Mn and EBITDA ....
Press Release · 16 Oct 2026, 7:18 pm
Solara Reports Record Q2'27 Results with EBITDA Surging 118% YoY Solara Active Pharma Sciences reported a strong Q2'27 performance, with revenue growing 33% YoY and 9% QoQ to INR 4,178 Mn. EBITDA surged 118% YoY and 21% QoQ to INR 769 Mn, expanding margins by 720 bps YoY to 18.4%. PAT turned around to INR 285 Mn from a loss of INR 101 Mn in Q2'26. Growth was driven by the base API business (revenue up 37% YoY to INR 3,273 Mn) and Ibuprofen narrowing EBITDA losses to INR 2 Mn. Net debt fell 19% to INR 5,000 Mn.
Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 8,300 Equity shares pursuant to exercise of ESOP options.
Others (Uncategorized) · 16 Oct 2026, 7:13 pm
Solara Active Pharma Sciences Approves Allotment of 8,300 Equity Shares Under ESOP Solara Active Pharma Sciences approved the allotment of 8,300 fully paid-up equity shares of face value Rs 10 each on 16th Oct'26 pursuant to the exercise of vested options under its Employee Stock Option Plan 2018. Issued at an exercise price of Rs 375 per share (including a premium of Rs 365), the company realized Rs 31,12,500 from the exercise. Following this allotment, the company's total paid-up equity capital increased to Rs 48,16,99,569 comprising 4,82,58,812 shares, with post-issue diluted EPS reported at Rs 6.16.
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter ....
Financial Result · 16 Oct 2026, 7:08 pm
Solara Active Pharma Reports Strong Q2 FY27 Results with PAT at Rs 28.46 Cr Solara Active Pharma Sciences reported consolidated revenue from operations of Rs 417.34 Cr for the quarter ended 30th Sep'26, up 33.1% YoY from Rs 313.54 Cr and 9.4% QoQ from Rs 381.60 Cr. Profit after tax stood at Rs 28.46 Cr, swinging from a net loss of Rs 10.10 Cr in the prior-year period, despite an exceptional loss of Rs 4.50 Cr on the sale of mothballed Vizag plant CWIP. Basic EPS reached Rs 5.92. Cumulative rights issue collections stood at Rs 446.62 Cr.
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter ....
Outcome · 16 Oct 2026, 7:06 pm
Solara Active Pharma Sciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 417 (+33.1% YoY | +9.4% QoQ) ■ EBITDA: 76.8 (+121.2% YoY | +24.0% QoQ) ■ EBITDA Margin (%): 18.4 (+734 bps YoY | +217 bps QoQ) ■ PAT: 28.5 (Loss to Profit YoY | +74.5% QoQ) ■ EPS (INR): 5.92 (Loss to Profit YoY | +68.2% QoQ)
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026, along with the Limited Review Report for the said period.
Outcome · 16 Oct 2026, 7:06 pm
Solara Active Pharma Reports Strong Q2 FY27 Turnaround with Net Profit at ₹28.46 Crore Solara Active Pharma Sciences reported consolidated revenue from operations of ₹417.34 crore for Q2 ended 30th Sep'26, up 33.1% YoY from ₹313.54 crore and 9.4% QoQ from ₹381.60 crore. Net profit stood at ₹28.46 crore, rebounding sharply from a net loss of ₹10.10 crore in Q2 ended 30th Sep'25 and up 74.5% QoQ from ₹16.31 crore, despite an exceptional loss of ₹4.50 crore on Vizag plant CWIP sale. Diluted EPS reached ₹5.92. Standalone Q2 revenue was ₹417.34 crore with net profit of ₹29.61 crore.
Solara Active Pharma Sciences Limited has informed the Exchange about the Schedule of Investors/Analysts call to be held on Friday, October 16, 2026, at 4.00 PM IST to discuss the Company''s ....
Intimation · 16 Oct 2026, 4:00 pm
Solara Active Pharma Schedules Q2FY27 Earnings Conference Call for 16th Oct'26 Solara Active Pharma Sciences Limited has scheduled an analyst and investor conference call on Friday, 16th Oct'26, at 4:00 PM IST to discuss its unaudited financial results for the quarter and half-year ended 30th Sep'26 (Q2FY27). The call will feature participation from senior leadership, including MD & CEO Sandeep Rao and CFO Sarat Kumar. Interested market participants can join via universal access numbers (+91 22 6280 1346 / +91 22 7115 8247) or pre-register via Diamond Pass.
Solara Active Pharma has informed the Exchange regarding the ESG Rating received from Crisil ESG Rating & Analytics Limited
Others (Uncategorized) · 10 Oct 2026, 11:55 pm
Solara Active Pharma Sciences ESG Rating Upgraded to Crisil ESG 63 Solara Active Pharma Sciences Limited received an upgraded Environmental, Social, and Governance (ESG) rating of 'Crisil ESG 63' under the 'Strong' category for FY26 (period ended 31st Mar'26) from Crisil ESG Ratings & Analytics Limited, up from 'Crisil ESG 56' for FY25. The rating was assigned independently without company engagement, evaluated on public disclosures and financial year information.
Update on approval of Final Reminder cum Forfeiture Notice for payment of outstanding call money.
Rights Issue · 09 Oct 2026, 10:39 pm
Solara Active Pharma Approves Fresh Forfeiture Notice for Rights Issue Call Money Solara Active Pharma Sciences Limited's Rights Issue Committee approved a circular resolution on 9th Oct'26 to issue a fresh Final Reminder-cum-Forfeiture Notice. The notice targets holders of partly paid-up rights equity shares who have failed to pay the outstanding First Call Money and/or Second and Final Call Money. The company is finalizing the notice details and will notify stock exchanges upon its dispatch.
Solara Active Pharma Sciences Limited has informed the Exchange about Board Meeting to be held on 16-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 16 Oct 2026, 5:30 am
Solara Active Pharma Sciences Ltd has informed the exchange that the meeting of the Board of Directors of the Company is scheduled to be held on Friday, October 16, 2026 ,inter alia, to consider and approve the unaudited Standalone and Consolidated financial results of the Company for the quarter and half year ended September 30, 2026.
Intimation · 16 Oct 2026, 5:30 am
Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/10/2026 ,inter alia, to consider and approve unaudited financial ....
Intimation · 16 Oct 2026, 5:30 am
Solara Active Pharma Schedules Board Meeting for Q2 Results on 16th Oct'26 Solara Active Pharma Sciences announced that its Board of Directors will meet on 16th Oct'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company securities has been closed for designated persons from 1st Oct'26 and will remain shut until 48 hours following the declaration of the financial results.
Intimation to furnish valid PAN. KYC details and Nomination by shareholders holding physical Shares
Others (Uncategorized) · 27 Sept 2026, 4:27 am
Solara Active Pharma Dispatches KYC and Nomination Reminders to Physical Shareholders Solara Active Pharma Sciences completed the dispatch of reminder letters on 26th Sep'26 to shareholders holding shares in physical mode, pursuant to SEBI's Master Circular. Physical shareholders are required to furnish their PAN, KYC, bank details, specimen signatures, and nominations to the RTA, Cameo Corporate Services. The RTA will freeze processing of service requests and complaints until these details are registered. Additionally, dividends for physical shareholdings will only be processed electronically.
Solara Active Pharma Sciences Limited has informed the exchange regarding the Voting Results and the Scrutinizer''s report of the Ninth Annual General Meeting
Annual General Meeting · 22 Sept 2026, 11:24 pm
Solara Active Pharma Sciences Limited has informed the Exchange regarding the Proceedings of Ninth Annual General Meeting held on September 18, 2026.
Annual General Meeting · 18 Sept 2026, 10:31 pm
Solara Active Pharma Sciences Limited has informed the exchange about intimation in connection with the receipt of Rectification Order
Others (Uncategorized) · 28 Aug 2026, 8:14 pm
Solara Active Pharma Receives Favorable Tax Rectification Order Solara Active Pharma Sciences has received a Rectification Order on 08 Aug'26 from the Income Tax Department concerning Assessment Year 2019-20. The order addresses a previous demand notice from 17 Mar'26 for ₹161.92 crores, which the company contested as incorrectly computed. Following Solara's application, the authority rectified the error, reducing the tax demand to nil. This favorable resolution eliminates the pending tax liability, resulting in no adverse financial or operational impact on the company. No further action is required from Solara.
Business Responsibility and Sustainability Reporting for the financial year 2025-26.
Others (Uncategorized) · 26 Aug 2026, 12:04 am
Solara Active Pharma Sciences: FY26 Business Responsibility and Sustainability Report Solara submitted its Business Responsibility and Sustainability Report for FY26 on 25 Aug'26. Exports contributed 52% of turnover. For FY26, total energy consumption was 9.62M GJ, with 81% from renewable sources, and total water consumption was 3.81L kL. GHG emissions (Scope 1+2) stood at 37,336 tCO₂e, an intensity of 7.47 tCO₂e/MT. Total waste generated was 27,208 MT. R&D and Capex for environmental/social improvements were 2% and 7% of their respective totals. Permanent employee turnover was 13%. The company targets a 90% GHG reduction by FY50.
Annual Report for the financial year ended March 31, 2026
Others (Uncategorized) · 25 Aug 2026, 11:57 pm
Solara Active Pharma Sciences Limited has informed the exchange about the dispatch of Notice of Ninth Annual General Meeting (AGM) of the Company scheduled to be held on Friday, September 18, 2026
Annual General Meeting · 25 Aug 2026, 11:46 pm
Conversion of Partly paid-up Rights Equity Shares into fully paid-up Equity shares in relation to the rights issue by the Company, upon receipt of Call Monies, as applicable.
Rights Issue · 19 Aug 2026, 4:42 pm
Solara Converts 2.79 Lakh Partly Paid-Up Rights Shares On 19th Aug'26, Solara's board approved converting 2,79,582 partly paid-up rights shares into fully paid-up equity shares (face value Rs. 10) upon receipt of call monies. This comprises 2,23,051 shares where a final call of Rs. 112.50 was paid, and 56,531 shares where calls totaling Rs. 243.75 were paid. The company will now seek listing and trading approvals for these converted shares, which will bear the ISIN INE624Z01016. The total paid-up capital stands at Rs. 48.16 crore.